TITLE

Linagliptin linked to better blood sugar in black patients with type 2 diabetes

AUTHOR(S)
Costa, Samantha; Fisher, Stacey L.; Foster, Melissa
PUB. DATE
June 2012
SOURCE
Endocrine Today;Jun2012, Vol. 10 Issue 6, p17
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress Meeting that was held in Philadelphia, Pennsylvania from May 23 to 27, 2012.
ACCESSION #
86259717

 

Related Articles

  • GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. Legakis, Ioannis // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2007, Vol. 1 Issue 3, p193 

    The gastrointestinal tract has a crucial role in the control of energy homeostasis through the action of multiple peptides known as incretins that act on distant target sites to promote the efficient uptake and storage of energy. In particular, GLP-1, an incretin hormone secreted from the...

  • Ileal Effect on Blood Glucose, HbA1c, and GLP-1 in Goto-Kakizaki Rats. Buchwald, Henry; Menchaca, Hector; Michalek, Van; Bertin, Nestor // Obesity Surgery;Nov2014, Vol. 24 Issue 11, p1954 

    Background: There have been enumerable studies on the effects of glucagon-like peptide-1 (GLP-1) on satiety and pancreatic islet function, stimulating the advocacy of surgical transposition of the ileum (rich in GLP-1-generating L-cells) higher in the gastrointestinal tract for earlier...

  • A Tripeptide Diapin Effectively Lowers Blood Glucose Levels in Male Type 2 Diabetes Mice by Increasing Blood Levels of Insulin and GLP-1. Zhang, Jifeng; Xue, Changyong; Zhu, Tianqing; Vivekanandan, Anuradha; Pennathur, Subramaniam; Ma, Zhongmin Alex; Chen, Y. Eugene // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant...

  • Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues. Raja, Umar Y.; Eastaugh, Alison E.; Younas, Mohammed S.; Hanif, Wasim // JRSM Cardiovascular Disease;2015, Vol. 4, p1 

    Glucagon like peptide (GLP-1) analogues are a relatively novel medication developed primarily for the treatment of type 2 diabetes since 2005. Although GLP-1 analogues have been shown to be more effective in the first few years of diagnosis in type 2 diabetes, we report a case of a patient with...

  • Tanzeum.  // MPR - Pharmacist's Edition;Winter2014/2015, Vol. 8 Issue 4, pA8 

    The article offers brief information on the Glucagon-like peptide-1 (GLP-i) receptor agonist Tanzeum for glycemic control in type two adults diabetics from GlaxoSmithKline.

  • Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Qing Qiao; Ouwens, Mario JNM; Grandy, Susan; Johnsson, Kristina; Kostev, Karel // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Jun2016, Vol. 9, p201 

    Aim: This study aimed to compare 6-month adherence to therapy with exenatide once weekly (Bydureon®) vs liraglutide once daily (Victoza®) in patients with type 2 diabetes under primary care in Germany. Methods: A nationwide longitudinal prescription database (LRx), (between January 2011...

  • Safety, tolerability, and nonglycemic effects of incretin-based therapies. Keith Campbell, R.; Cobble, Michael E.; Reid, Timothy S.; Shomali, Mansur E. // Journal of Family Practice;Sep2010 Supplement, Vol. 59, pS20 

    The article focuses on the tolerability, safety, and nonglycemic effects of incretin-based therapies for the treatment of type 2 diabetes mellitus (T2DM). It states that the use of glucose-lowering medications which reduced associated risk factors and indicates favorable safety profile shows...

  • Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Zander, Mette; Christiansen, Allan; Madsbad, Sten; Juul Holst, Jens; Holst, Jens Juul // Diabetes Care;Aug2004, Vol. 27 Issue 8, p1910 

    Objective: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes.Research Design and Methods: Eight patients with type 2 diabetes (BMI 32.7 +/- 1.3 kg/m(2) and fasting plasma glucose 13.5 +/-...

  • Victoza.  // Formulary;Mar2010, Vol. 45 Issue 3, p76 

    The article focuses on the new molecular entity liraglutide (Victoza) by Novo Nordisk which is a glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. It was approved by the U.S. Food and Drug Administration in January 2010 and is indicated as an addition to diet and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics